Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Biberach – page 48

668 clinical trials in Biberach, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Biberach at a glance
668
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

668 trials in Biberach

Open in trial search

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:ITM Solucin GmbH

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deutivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Dimethyl Fumarate
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness and Safety of Crovalimab vs. Eculizumab for Adults and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Treated with Complement Inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crovalimab
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Psoriasis

Not recruiting

Study Comparing Risankizumab and Deucravacitinib for Adults with Moderate Plaque Psoriasis Eligible for Systemic Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Study Comparing Pirtobrutinib with Idelalisib and Rituximab or Bendamustine and Rituximab for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Idelalisib
  • Sponsor:Loxo Oncology Inc.

Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Safety and Effectiveness of Polatuzumab Vedotin with Rituximab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:F. Hoffmann-La Roche AG

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Biberach

What the registry says about research in the country

01 Eye Diseases and Related Research

In Biberach An Der Riss, much of the clinical trial activity is connected to eye diseases and broader investigational research in healthy volunteers. The studies are focused on understanding how new treatments are absorbed, how food affects them, and how they interact with other medicines.

  • Research involving Eye Diseases and unspecified disease areas
  • Studies in healthy volunteers and otherwise healthy participants
  • Trials exploring pharmacokinetics and medicine interactions
  • Work aimed at improving treatment use and safety for future care

These trials help clarify how candidate therapies behave in the body and support the development of better treatment options.

02 Pharmacokinetic Studies

A major part of the research landscape centers on pharmacokinetic trial work, especially in healthy people. These studies are designed to see how medicines are absorbed, distributed, and influenced by food or other drugs.

  • Testing how different formulations are taken up in the body
  • Checking the effect of food on medicine exposure
  • Evaluating possible drug-drug interactions
  • Supporting the safe development of new oral therapies

The goal is to build a clearer picture of how investigational medicines behave before wider clinical use.

03 Healthy Volunteer Trials

Many of the studies in this city involve healthy volunteer trial designs, which are used to test safety, tolerability, and how the body responds to new compounds. This research is essential for early evaluation of promising medicines.

  • Assessing how well new treatments are tolerated
  • Comparing tablet and injection-style formulations
  • Measuring exposure changes with common co-medications
  • Generating data that supports further clinical development

The emphasis is on careful observation of how healthy participants respond to study medicines.

04 Metabolic and Cardiovascular Research

Some trials also address broader metabolic and cardiovascular interests, including medicines studied for body weight-related conditions and heart effects. These projects aim to understand both benefit and safety across different formulations.

  • Research on therapies related to obesity and metabolism
  • Studies of heart-related effects and medicine exposure
  • Comparisons of separate versus combined medicine use
  • Support for better treatment planning in chronic disease care

This area reflects a wider effort to refine new treatments for complex health conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.